Publication | Open Access

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

First-line TherapyEsophageal CancerGastroesophageal JunctionAdvanced Her2-negative GastricMedicineGastrointestinal OncologyGastroenterologyPathologyCancer TreatmentOncologyRadiation Oncology